Hydroxychloroquine administration in pregnancy

Suhonen, R.

doi:10.1001/archderm.119.3.185a

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent study of 251 SLE patients with 263 pregnancies, HCQ was associated with a lower risk (OR = 0.3, 95% CI = 0.1–0.7, P = 0.01) of adverse pregnancy outcomes (stillbirth, premature birth, IUGR). Since 1983, case reports and case series on HCQ use during pregnancy and breast‐feeding have not reported an increased incidence of abnormalities in fetal outcomes or in early childhood development . Given the reported safety profile of HCQ in pregnancy, there has been a rise in HCQ use during pregnancy in the past 13 years (from 6.3% in 2005 to 60.9% in 2017) …”

Section: Safety Of Hcq In Pregnancymentioning

confidence: 99%

Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage

Moreuil

Alavi

Pasquier

2019

Brit J Clinical Pharma

View full text Add to dashboard Cite

Recurrent miscarriage (RM) and vasculoplacental disorders, such as preeclampsia (PE), affect women of childbearing age worldwide. Vascular endothelial dysfunction and immunological impairment are associated with both RM and PE. To date, there is no effective or optimal therapeutic approach for these conditions. Notably, aspirin use is only partially effective in the prevention of PE. Hydroxychloroquine (HCQ) has demonstrated beneficial effects on disease flares, pregnancy outcomes and cardiovascular impairment in systemic erythaematosus lupus (SLE) through its immunomodulatory, vasculoprotective and antithrombotic properties. Here, in the context of the underlying physiological dysregulation associated with PE and RM, the beneficial properties and potential therapeutic efficacy of HCQ are reviewed in anticipation of the results of current and future trials. Two related trials addressing RM in the absence of maternal autoimmune disease are ongoing. Other trials addressing pregnancy outcomes in the presence of maternal autoimmune disease are forthcoming. In this review, we hypothesise that the immunological and endothelial effects of HCQ may be beneficial in the context of PE and RM, regardless of the maternal autoimmune status. K E Y W O R D S hydroxychloroquine, pregnancy, preeclampsia, recurrent miscarriage

show abstract

Section: Safety Of Hcq In Pregnancymentioning

confidence: 99%

Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage

Moreuil

Alavi

Pasquier

2019

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…In this series, similar to ours, the other six normal, full-term, spontaneous deliveries resulted in normal babies with no congenital abnormalities. Discoid lupus C 250 mg twice daily at some time (two throughout pregnancy) throughout four of seven completed pregnancies Suhonen 21 Ross and Garatos 22 Wolfe In summary, although fetal wastage occurred mostly in patients with active SLE, this cannot be attributed only to SLE disease activity, since other risk factors (such as antiphospholipid antibodies) associated with fetal wastage were not evaluated, and it occurred also in patients with RA and those treated for malaria prophylaxis. Because fetal wastage is occurring spontaneously in high rates, a large number of patients will be needed to address an independent role of C and HC in causing this adverse event, as well as the absence of associated congenital abnormalities, when given throughout pregnancy.…”

Section: Discussionmentioning

confidence: 99%

“…Another three pregnancies of the same woman in which the fetuses were not exposed to the drug ended in normal infants. Suhonen 21 described a 23-year-old woman who took 200 mg/day of HC during the first 16 weeks of pregnancy as therapy for discoid lupus erythematosus. The pregnancy proceeded and a healthy male infant was born.…”

Section: Discussionmentioning

confidence: 99%

Pregnancy Outcome Following First Trimester Exposure to Chloroquine

Levy¹,

Buskila²,

Gladman³

et al. 1991

Amer J Perinatol

111

View full text Add to dashboard Cite

Although the use of chloroquine (C) and hydroxychloroquine (HC) in the treatment of malaria prophylaxis during pregnancy is probably safe, the use of much higher doses for treatment of systemic lupus erythematosus (SLE) and rheumatoid arthritis during pregnancy has been controversial. We analyzed the cases of 24 pregnant women with a total of 27 pregnancies who had taken these drugs during their first trimester of pregnancy. C and HC were given in 11 patients with SLE, three with rheumatoid arthritis, and four for malaria prophylaxis. Most of these women had already been on antimalarial drugs for 1 to 172 months prior to pregnancy (mean, 32.2 months). Of the 27 pregnancies, 14 resulted in normal full-term deliveries, six were aborted due to severe disease activity or social conditions, three were stillbirths, and four pregnancies resulted in spontaneous abortions. No congenital abnormalities were detected in the 14 live births at ages between 9 months and 19 years (mean, 5.3 years). All these children are physically and developmentally normal with no clinical evidence of eye or hearing defects. The seven pregnancies that were associated with fetal loss occurred particularly in patients who had active SLE, although stillbirth and spontaneous abortion occurred also in patients with rheumatoid arthritis and in two of the three patients who had been treated prophylactically for malaria. Although of the 215 reported pregnancies with C and HC exposure, including our study, only seven (3.3%) had congenital abnormalities, the risk associated with antimalarials may be cumulative and further studies are needed to elucidate the safety of this drug later in pregnancy.

show abstract

“…They concluded that hydroxychloroquine seems to be safe during pregnancy and preterm delivery reflects the state of maternal disease [12]. Suhonen reported a case receiving hydroxychloroquine phosphate in the first six weeks of pregnancy to control discoid systemic lupus erythematosus and fetus was born with no anomalies and grew without any mental or physical abnormalities [13]. Ross and Garotos examined autopsy from 14-week aborted fetus as his mother taking chloroquine showing no anomalies in oropharynx [14].…”

Section: Chloroquine and Hydroxychloroquinementioning

confidence: 99%

A Scoping Review of the Effects of COVID-19 Medications on Pregnancy

Abbas¹

2020

WJGWH

View full text Add to dashboard Cite

COVID-19 is a pandemic disease caused by the SARS-CoV-2 which began to appear around in December 2019 in Wuhan, China and spread globally in the last few months. Currently, there is no specific treatment for SARS-CoV-2 which forced clinicians to use old drugs, chosen for their efficacy against similar viruses or their in vitro activity. The majority of information comes from small case series and single center reports which showed that COVID-19 infection in pregnant women can lead to intrauterine growth restriction, premature labor and spontaneous abortion. So, in the view of the urgency of COVID-19 pandemic and the uncertainties about its management during pregnancy, we aimed to provide a literature review on the effectiveness and safety of available medications for COVID-19 in pregnant women. Here, our overview may provide useful information for physicians to choose the best available medications for treatment a pregnant case with COVID-19.

show abstract

Hydroxychloroquine administration in pregnancy

Cited by 6 publications

References 0 publications

Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage

Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage

Pregnancy Outcome Following First Trimester Exposure to Chloroquine

A Scoping Review of the Effects of COVID-19 Medications on Pregnancy

Contact Info

Product

Resources

About